Oral semaglutide (Rybelsus)

The only FDA-approved GLP-1 in pill form. A swallowed daily tablet approved for type 2 diabetes, with modest weight loss at current doses and a higher-dose obesity version on the way.

What oral semaglutide is Rybelsus is semaglutide formulated as a once-daily swallowed tablet. A carrier molecule (SNAC) protects the peptide from stomach acid long enough for a small fraction to absorb. That makes it the only GLP-1 you can take entirely without needles and with FDA approval — but the trade-offs are real: - Strict dosing ritual. It must be taken on an empty stomach with no more than ≈4 oz of water, then nothing to eat or drink for 30 minutes. Skipping the ritual tanks absorption. - Daily, not weekly. Adherence demands are higher than weekly injections. - Modest weight loss at approved doses. The PIONEER diabetes trials showed meaningful A1c reduction but weight loss of roughly 3–5 kg — far below injection-dose semaglutide. ## The higher-dose future The OASIS trial program tested oral semaglutide 25–50 mg for obesity: the 25 mg dose produced weight loss approaching injectable Wegovy levels (≈15% in OASIS 4), and a 25 mg obesity-indication version has been submitted to regulators. If approved, a true “Wegovy in a pill” changes the needle-free landscape substantially — check the retatrutide and pipeline page for what else is coming. ## Oral vs. sublingual — do not confuse them | | Rybelsus (oral) | Sublingual compounded | | --- | --- | --- | | FDA-approved | Yes (for diabetes) | No | | How it absorbs | Swallowed; stomach absorption via SNAC carrier | Under the tongue; oral-mucosa absorption | | Schedule | Daily, fasting ritual | Typically weekly | | Evidence | Large randomized trials (PIONEER, OASIS) | No randomized trials | ## Who considers it People with type 2 diabetes who want a GLP-1 without injections; needle-averse patients who prefer an FDA-approved option over compounded sublinguals and accept more modest weight results at current doses.